Blog – Warren Peptides (ARL)

News

Cross-Validating Retatrutide ELISA Kits Against LC-MS/MS for Plasma Quantification

August 6, 2026|Caleb Cross

Cross-validating Retatrutide ELISA kits against LC-MS/MS reveals systematic bias from metabolite cross-reactivity. A 2024 study shows ELISA

Quantifying Retatrutide Degradation Products in High-Temperature Compounded Formulations

August 3, 2026|Caleb Cross

A forced-degradation study subjected retatrutide formulations to high heat, identifying and quantifying breakdown products. The results map thermal

Assessing Epitalon Bioavailability in Oral Formulations

July 30, 2026|Caleb Cross

In vitro digestion models reveal rapid enzymatic degradation of Epitalon, with less than 15% surviving gastric conditions. This article examines formulation

Your cart is empty

News

Cross-Validating Retatrutide ELISA Kits Against LC-MS/MS for Plasma Quantification

Cross-Validating Retatrutide ELISA Kits Against LC-MS/MS for Plasma Quantification